Crothall partners Surfacide to take new step in UV-C disinfection
Offers three-emitter Helios system to control drug-resistant bugs
Crothall Healthcare, a US provider of healthcare support services, has partnered Surfacide, a Naperville, IL-based manufacturer of UV-C disinfection systems, to create a three-emitter Helios UV-C disinfection system, which is said to be effective at controlling C.Diff, CRE, Acinetobacter, MRSA, and other drug-resistant micro-organisms.
The Wayne, PA-based firm says that although existing UV technology has demonstrated a degree of effectiveness, the limitations of having only one emitter in the room have proven significant. Its inability to introduce effective energy levels to all areas of the patient environment resulted in treatment ‘shadows’. To overcome this, hospitals often had to move the emitter and leave spaces that could not be reached, tripling the time required before a new patient could be admitted. Using a three-emitter system approach results in being closer to all surfaces in the room. Surfacide provides validation of total delivered energy through its proprietary laser mapping technology that can be downloaded to a handheld tablet computer. The end result is more energy, delivered to every surface, in less time, with visual confirmation at your fingertips, the firm says.
‘Given Crothall's experience with UV disinfection and its reputation as a leading provider of environmental services, we view this strategic partnership as a great endorsement of the Surfacide Helios system,’ said Gunner Lyslo, Founder and Chief Executive of Surfacide. ‘Together, we are providing a solution to healthcare facilities that empowers them with the most effective and cost-efficient UV-C disinfection system on the market.’
Crothall is currently overseeing its first Surfacide Helios UV-C system installation at the Ohio State University Medical Centre in Columbus.
